ALKS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alkermes Plc (ALKS) is not a strong buy for a beginner investor with a long-term strategy at this time. The lack of significant positive catalysts, declining financial performance, and neutral trading sentiment suggest holding off on investment until clearer growth trends or stronger signals emerge.
The MACD is positive and expanding, indicating bullish momentum. RSI is in the neutral zone at 72.167, showing no overbought or oversold conditions. Moving averages are converging, suggesting a lack of a strong trend. The stock is trading near its resistance level (R1: 29.686), which may limit immediate upside potential.
Analysts maintain optimistic long-term views on the company's narcolepsy franchise, with Lumryz and alixorexant as key growth drivers. Gross margin increased YoY, reflecting operational efficiency.
Revenue, net income, and EPS have all declined significantly YoY in the latest quarter (2025/Q4). No recent news or significant insider or hedge fund activity. Congress trading data is absent. The stock has a 70% chance of declining slightly in the short term.
In 2025/Q4, revenue dropped by -10.57% YoY to $384.55M. Net income fell by -66.32% YoY to $49.34M, and EPS declined by -67.05% YoY to $0.29. However, gross margin improved by 2.84% YoY to 87.98%.
Analysts have mixed ratings. Piper Sandler and Wolfe Research are optimistic, with price targets of $43-$45 and Overweight/Outperform ratings. H.C. Wainwright and BofA are more cautious, with Neutral ratings and lower price targets of $34-$43. Analysts highlight the company's emerging narcolepsy franchise as a key growth area but note challenges with legacy products.
